Tech-enabled preventive health startup Neko Health banked $700 million, backed by celebrities Claudia Schiffer, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, to break into the U.S. market with plans to open a New York City clinic later this year.
The company, founded by Daniel Ek, the founder and former CEO of Spotify, and Hjalmar Nilsonne, offers non-invasive, radiation-free diagnostic scans that it says captures millions of health data points. Neko Health does not use large medical imaging machines like MRIs for its scans unlike competitors Prenuvo and Ezra, now owned by Function Health.
Neko Health captures data across an individual's skin, heart, blood and metabolic health. Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks, biomarkers to identify pre-diabetes risk, as well as blood abnormalities, and risk factors linked to metabolic syndrome, stroke and heart attack. Customers get results on-site and have an in-person consultation with a medical professional to discuss the findings.
Neko upgraded its health scans to now include wearables integration and body composition analysis.
The scans are priced at £299 in the U.K., about $341 in U.S. dollars based on current exchange rates. The company did not disclose the cost of the scans in the U.S. market.
Lightspeed Venture Partners and O.G. Venture Partners co-led the series C round, with participation from existing investors Atomico, General Catalyst and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum and BDT & MSD. As part of the round, David Ofer of O.G. Venture Partners will join the board of directors.
The funding round also saw participation from Ari Emanuel, Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Thierry Henry, Tim Ferriss and will.i.am, joining existing investors including Alexis Ohanian from Seven Seven Six, Alex Tew and Michael Acton-Smith from Calm, Gary Vaynerchuk, Jessie Inchauspé, Katie Haun, Raj Shamani, Steven Bartlett, Zoë Saldaña and Marco Perego-Saldaña.
The company did not disclose its valuation.
Neko Health raised $260 million in series B funding in January 2025.
Launched in 2023, the company operates clinics in Sweden and the U.K., including Manchester, Birmingham and multiple locations in London. Over 350,000 people have joined a waitlist or registered for a scan, and more than 100,000 members have already experienced one, according to the company. Neko Health says, on average, 75% of members book and prepay a scan for the following year at the end of their appointment.
Neko Health says it builds its technology in-house, including hardware, software and consumer experience. Executives assert that this enables the company to control the experience from start to finish, to move faster and to improve continuously.
Last month, Neko opened its latest clinic in Stockholm, built around the next generation of Neko-engineered medical devices, Derma-2, Echo-2 and Spectrum-2, each upgraded to capture a greater volume and higher fidelity of health signals across skin, heart and circulation. This next-generation hardware will be rolled out across all Neko clinics in the next few months.
The company plans to the use the funding to fuel its growth in the U.S. and invest in its technology.
"Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale. We believe this is one of the most important healthcare companies of our generation, and we're proud to deepen our partnership as they continue to reimagine prevention," said Bejul Somaia, global partner at Lightspeed Venture Partners.
Elective, direct-to-consumer full-body scanning is a growing market fueled by advances in artificial intelligence to make the scans faster. The market was valued at $29.7 billion in 2025 and is projected to reach $47.2 billion by 2033, according to data from SNS Insider.
Major players in the market include Prenuvo, Ezra, which merged with Function Health, and SimonMed. Prenuvo raised $120 million in 2025 and now operates 29 clinics, mostly in the U.S. with three clinics in Vancouver, Canada, London and Melbourne, Australia.
Function Health, a preventive health and longevity startup, acquired Ezra in May 2025 to integrate Function’s lab testing capabilities with the company’s AI-powered full-body scans. The company banked a $300 million series B round in November.